Aclasta Consumer Home

Aclasta® is a prescription medicine for the treatment and prevention of osteoporosis and the treatment of Paget’s disease of the bone. Aclasta is an infusion and contains 5mg of zoledronic acid. Check with your doctor to see if Aclasta is right for you. Aclasta is fully funded for patients who meet specified criteria. Funding does not include the cost of infusion and normal doctors and prescription charges will apply. Do not use if you are pregnant or breast feeding. Not recommended in patients with kidney impairment or in children and adolescents. Caution while under dental treatment or if dental treatment is planned. Calcium, hydration status and kidney function may be assessed by your doctor before and after you are given Aclasta. Adverse effects are usually mild and transient. Common side effects are flu-like symptoms consisting of fever, fatigue, chills, and bone, joint, and/or muscle pain; anaemia; headache; dizziness, transient low blood calcium; gastrointestinal symptoms, renal impairment, breathing difficulty and lethargy. Very rarely osteonecrosis of the jaw has been reported. If symptoms persist or you have side effects see your doctor. Aclasta is the registered trademark of Novartis AG. Novartis New Zealand Limited, Auckland. For further information check the Consumer Medicine Information [CMI] at www.medsafe.govt.nz. ACL 0211-080-0213 and TAPS NA4761.